Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : NEW DUPIXENT (DUPILUMAB) DATA IN PATIENTS AS YOUNG AS SIX YEARS OLD WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TO BE PRESENTED AT WCPD AND EADV

09/22/2021 | 10:08am EDT

More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents and adults

Results provide insight into the clinical and real-world experience of Dupixent on disease measures including itch, disease severity, sleep, and anxiety

Dupixent presentations include longest duration of data for any biologic medicine in adults with moderate-to-severe atopic dermatitis, with results up to 3.5 years

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that new Dupixent (dupilumab) analyses in patients as young as six years old with moderate-to-severe atopic dermatitis will be presented at the 14th World Congress of Pediatric Dermatology Annual Congress (WCPD) from September 22-25 and the 30th European Academy of Dermatology and Venereology Congress (EADV) from September 29-October 2.

'Moderate-to-severe atopic dermatitis can severely affect people from infancy into adulthood, often causing a lifetime of debilitating symptoms like intense itch, skin lesions covering much of the body, impaired mental well-being and an increased risk of skin infections,' said Bola Akinlade, M.D., Vice President, Clinical Sciences, Immunology and Inflammation at Regeneron. 'Our broad portfolio of data at WCPD and EADV helps provide much-needed insight into the long-term effects of the disease, as well as the impact of Dupixent on physical symptoms and quality of life measures through different stages of life.'

Notable Dupixent presentations include long-term efficacy and safety data showing the impact of Dupixent on signs and symptoms of moderate-to-severe atopic dermatitis in children, adolescents and adults. More than 30 presentations highlight Dupixent results on skin lesions, itch and skin infections, as well as sleep and health-related quality of life, for patients and their families, such as in adults with a history of mental health disorders and in children with anxiety and depression. Real-world evidence will also be presented from observational registries and claims databases across multiple geographies.

Disease burden data to be presented at EADV include results from the Atopic Dermatitis Global Adolescent and Pediatric survey on how patients, caregivers and physicians view the full impact of moderate-to-severe atopic dermatitis, based on findings from more than 3,900 people across 13 countries. Data will also be shared from the Quality of Care in AD Initiative, which documents best practices from 32 atopic dermatitis centers across the world, focused on the value of patient education and communication.

Data to be presented at WCPD 2021

Clinical Efficacy and Safety of Dupixent in Atopic Dermatitis

Oral presentation (September 24, 3:40-3:50 pm BST):

#SP42 Long-Term Efficacy and Safety Data for Dupilumab in a Phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in Patients Aged 6 to < 12 Years With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD), Michael Cork

Poster #P22: Efficacy and Safety of Dupilumab for up to 1 Year in a Phase 3 Open-Label Extension (OLE) Trial (LIBERTY AD PED-OLE) in Adolescents With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD), Andrew Blauvelt

Poster #P23: 52-Week Laboratory Safety Findings From an Open-Label Extension (OLE) Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE), Michael Cork

Poster #P33: Dupilumab Improved Itch in Children Aged 6-11 Years With Severe Atopic Dermatitis: Analysis From the LIBERTY AD PEDS Trial, Gil Yosipovitch

Poster #P35: IGAxBSA: An Alternative to EASI in Assessing Disease Severity and Response in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis, Amy Paller

Poster #P36: Dupilumab Induces Rapid and Sustained Improvement in Clinical Signs in Children With Severe Atopic Dermatitis, Amy Paller

Poster #P38: Dupilumab Significantly Improves All POEM Components in Children Aged 6 to

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about REGENERON PHARMACEUTICALS
04:50aSANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
04:24aREGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
01:50aSANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
10/20SANOFI : Regeneron Win Expanded US FDA Nod for Asthma Drug Dupixent
MT
10/20REGENERON PHARMACEUTICALS : Sanofi Say FDA Has Expanded Approval of Dupixent to Include Ch..
MT
10/20REGENERON PHARMACEUTICALS : FDA Expands Approval of Dupixent® (dupilumab) to Include Child..
PR
10/14REGENERON PHARMACEUTICALS : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Tr..
MT
10/14Health Care Stocks Climb Pre-Bell Thursday
MT
10/14REGENERON PHARMACEUTICALS : US FDA Accepts Regeneron's Regen-Cov For Priority Review for C..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 14 402 M - -
Net income 2021 7 227 M - -
Net Debt 2021 - - -
P/E ratio 2021 8,60x
Yield 2021 -
Capitalization 59 196 M 59 196 M -
Capi. / Sales 2021 4,11x
Capi. / Sales 2022 4,85x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 569,37 $
Average target price 681,64 $
Spread / Average Target 19,7%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS17.86%59 196
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.25.77%65 142
VERTEX PHARMACEUTICALS-20.84%48 536
BEIGENE, LTD.45.24%35 024